These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27079900)

  • 1. Projected economic evaluation of the national implementation of a hypothetical HIV vaccination program among adolescents in South Africa, 2012.
    Moodley N; Gray G; Bertram M
    BMC Public Health; 2016 Apr; 16():330. PubMed ID: 27079900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Case for Adolescent HIV Vaccination in South Africa: A Cost-Effectiveness Analysis.
    Moodley N; Gray G; Bertram M
    Medicine (Baltimore); 2016 Jan; 95(4):e2528. PubMed ID: 26825890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of a modestly effective HIV vaccine in the United States.
    Long EF; Owens DK
    Vaccine; 2011 Aug; 29(36):6113-24. PubMed ID: 21510996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model.
    Hontelez JA; Nagelkerke N; Bärnighausen T; Bakker R; Tanser F; Newell ML; Lurie MN; Baltussen R; de Vlas SJ
    Vaccine; 2011 Aug; 29(36):6100-6. PubMed ID: 21703321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.
    Selinger C; Bershteyn A; Dimitrov DT; Adamson BJS; Revill P; Hallett TB; Phillips AN; Bekker LG; Rees H; Gray G
    Vaccine; 2019 Apr; 37(16):2258-2267. PubMed ID: 30890385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.
    de Montigny S; Adamson BJS; Mâsse BR; Garrison LP; Kublin JG; Gilbert PB; Dimitrov DT
    Sci Rep; 2018 Apr; 8(1):6066. PubMed ID: 29666455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X; Stander MP; Van Kriekinge G; Demarteau N
    BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Male circumcision at different ages in Rwanda: a cost-effectiveness study.
    Binagwaho A; Pegurri E; Muita J; Bertozzi S
    PLoS Med; 2010 Jan; 7(1):e1000211. PubMed ID: 20098721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa.
    Bos JM; Postma MJ
    Pharmacoeconomics; 2001; 19(9):937-46. PubMed ID: 11700780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results.
    Andersson KM; Paltiel AD; Owens DK
    Vaccine; 2011 Aug; 29(36):6107-12. PubMed ID: 21736912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of school-located influenza vaccination programs for elementary and secondary school children.
    Yoo BK; Schaffer SJ; Humiston SG; Rand CM; Goldstein NPN; Albertin CS; Concannon C; Szilagyi PG
    BMC Health Serv Res; 2019 Jun; 19(1):407. PubMed ID: 31234842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
    Andersson KM; Stover J
    Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa.
    Amirfar S; Hollenberg JP; Abdool Karim SS
    J Acquir Immune Defic Syndr; 2006 Oct; 43(2):219-25. PubMed ID: 16951648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.
    Adamson B; Garrison L; Barnabas RV; Carlson JJ; Kublin J; Dimitrov D
    J Int AIDS Soc; 2019 Aug; 22(8):e25373. PubMed ID: 31402591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program.
    Pearson AL; Kvizhinadze G; Wilson N; Smith M; Canfell K; Blakely T
    BMC Infect Dis; 2014 Jun; 14():351. PubMed ID: 24965837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
    Patel HD; Roberts ET; Constenla DO
    Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
    Long EF; Stavert RR
    J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
    Tan N; Sharma M; Winer R; Galloway D; Rees H; Barnabas RV
    Vaccine; 2018 Aug; 36(32 Pt A):4830-4836. PubMed ID: 29891348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.